Novartis Statement: Cystinosis Stem Cell Gene Therapy Program

Print Friendly, PDF & Email

In May 2023, Novartis acquired the investigational autologous hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis from AVROBIO. In their first public statement to the cystinosis community, they’ve shared:

“Novartis Gene Therapies is committed to working with our partners in the cystinosis community by collaborating with each advocacy group to hear the community voice and further understand what is important to you as we develop this new therapy.”

Read the full Community Statement here.